The 4th Fc-Mediated Function Summit 2024 was held in Boston, MA from April 17-18, and focused on discussions supercharging FcRn, FcγR, and IgG to advance molecular development, clinical utility, and novel therapeutic applications. During the event, industry experts from across the globe gathered to share the latest research in Fc biology insights, including:
Translating Fc Biology Insights to Innovate Drug Design
Fc Receptor Role in IO Drug Development to Transfer in Autoimmunity
Developing Antibody Target Engagement & Fc-Mediated Function
Targeting FcγR - What is the Next Mutation?
Biointron Summary Report:
1. Innovative Drug Design
Understanding Fc biology, effector functions, and inhibitors to discover opportunities to improve antibody therapeutics.
Using Fc Factor 8 to activate NK cells for specific targeting of unwanted B-cells.
Showcase of mouse models expressing human Fc receptors as tools for translational assessment of Fc receptor-targeted therapies.
2. Autoimmunity
Systemic IgA may be exploited for potential novel therapeutics strategies against infectious disease.
Next generation formats like tetravalent bispecific antibodies in the Fc are beneficial for cancer immunotherapy.
The combination of checkpoint blocking and Fc-mediated tumor cell killing can lead to novel cancer therapeutics.
3. Fc-Mediated Functions
Engineered antibody and albumin molecules with tailored binding and transport properties was discussed.
Evaluation of the main Fc silencing mutations, and what specific needs there are is useful for enhancing diesign optimization.
4. Targeting FcγR
Using the potential of Fc gamma receptors to tune antibody-based immunotherapy with tailored FcgR-blockade.
PD-1 agonist antibodies rely on the mediated clustering of FcγRs to trigger their sppresive function.
Thank you to everyone who visited our booth at the 4th Fc-Mediated Function Summit 2024 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
